The DOI matches its Crossref record.
Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Abstract
Cancer has been cursed for human beings for long time. Millions people lost their lives due to cancer. Despite of the several anticancer drugs available, cancer cannot be cured; especially at the late stages without showing any side effect. Heterocyclic compounds exhibit exciting medicinal properties including anticancer. Some market selling heterocyclic anticancer drugs include 5-flourouracil, methortrexate, doxorubicin, daunorubicin, etc. Besides, some natural products such as vinblastine and vincristine are also used as anticancer drugs. Overall, heterocyclic moeities have always been core parts in the expansion of anticancer drugs. This article describes the importance of heterocyclic nuclei in the development of anticancer drugs. Besides, the attempts have been made to discuss both naturally occurring and synthetic heterocyclic compounds as anticancer agents. In addition, some market selling anticancer heterocyclic compounds have been described. Moreover, the efforts have been made to discuss the mechanisms of actions and recent advances in heterocyclic compounds as anticancer agents. The current challenges and future prospectives of heterocyclic compounds have also been discussed. Finally, the suggestions for syntheses of effective, selective, fast and human friendly anticancer agents are discussed into the different sections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Indole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
The recent progress of isoxazole in medicinal chemistry
Zhu, J., Mo, J., Lin, H.-Z., Chen, Y., & Sun, H.-P. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.013 · Cited by 417
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Self-citationNanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s289443 · Cited by 390
Pyrrole: An insight into recent pharmacological advances with structure activity relationship
Ahmad, S., Alam, O., Naim, M. J., Shaquiquzzaman, M., Alam, M. M., & Iqbal, M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.002 · Cited by 259
Metadata
- Authors
- Ali, I., Lone, M., Al-Othman, Z., Al-Warthan, A., & Sanagi, M.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-07-27
- Volume
- 16
- Issue
- 7
- Pages
- 711-734
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2129094690
- Cited by
- 252
- References
- 0
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. https://app.cochat.ai/papers/10.2174/1389450116666150309115922
- The paper
- Ali, I., Lone, M., Al-Othman, Z., Al-Warthan, A., & Sanagi, M. (2015). Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. Current Drug Targets. https://doi.org/10.2174/1389450116666150309115922
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.